22 December 2015 - On December 21, the U.S. FDA approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478599.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery